Author

B. A. Hanks

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

B. Theivanthiran· 2 shared G. Beasley· 2 shared M. P. Plebanek· 2 shared N. Yarla· 2 shared Y.-V. Nguyen· 2 shared A. Holtzhausen· 1 shared A. V. DiMarco· 1 shared B. McKinney· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Theivanthiran

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Gli2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating Wnt Ligand and Prostaglandin Signaling

N. C. DeVito, Y.-V. Nguyen, M. Sturdivant, M. P. Plebanek, K. Howell, N. Yarla, V. Jain, M. Aksu, G. Beasley, B. Theivanthiran, B. A. Hanks

This paper identifies Gli2 as a key driver of immune evasion and immunotherapy resistance in tumors through Wnt and prostaglandin signaling, offering a therapeutic target for combination immunotherapies.

bioRxiv · Mar 31, 2024Cancer Biology

A SREBF2-dependent gene program drives an immunotolerant dendritic cell population during cancer progression

M. P. Plebanek, Y. Xue, Y.-V. Nguyen, N. DeVito, X. Wang, A. Holtzhausen, G. Beasley, N. Yarla, B. Theivanthiran, B. A. Hanks

The paper identifies SREBF2 as a regulator of mregDC development and function in the tumor microenvironment, highlighting it as a therapeutic target for immune tolerance.

bioRxiv · Apr 26, 2023 · PreprintImmunology

APOBEC mutagenesis inhibits breast cancer growth through induction of a T cell-mediated antitumor immune response

A. V. DiMarco, X. Qin, S. Van Alsten, B. McKinney, N. M. G. Garcia, J. Force, B. A. Hanks, M. A. Troester, K. Owzar, J. Xie, J. V. Alvarez

This study shows that APOBEC mutagenesis in breast cancer promotes T cell-mediated antitumor immunity, leading to tumor growth inhibition and sensitivity to checkpoint inhibitors.

bioRxiv · Feb 13, 2021Cancer Biology